Beyond borders: Biotechnology report 2017 – Staying the course

It was supposed to be a bad year for biotech. For this sector, the simplest of truisms has always held: what goes up must eventually come down. Markets peaked in 2015 and declined in 2016; payer pressure and US election year rhetoric weighed on the sector; drug approvals fell sharply; and biotech companies faced a … More Beyond borders: Biotechnology report 2017 – Staying the course